Confusion over AstraZeneca-EU talks on vaccine delay
A European Commission spokeswoman, Dana Spinant, told journalists the situation with AstraZeneca executives was "evolving".
"I can't say whether AstraZeneca will be represented," she said, adding that some input was expected from the firm during the meeting.
Public communication on the issue has become increasingly sharp.
But AstraZeneca CEO Pascal Soriot said in an interview given on Tuesday that his firm was bound only to make its "best effort" to deliver the doses.
"We didn't commit with the EU... It's not a commitment we have to Europe," he said.
He also said that former EU member Britain -- which has been rolling out AstraZeneca vaccine jabs at a high pace -- had a headstart on the European Union by signing its contract three months earlier, giving time to iron out "glitches" in UK vaccine plants.
A senior EU official on Wednesday rejected those points made by Soriot.
"We contest many of the things in the interview, including the idea that the factories in the UK are reserved for UK deliveries. It's not true," the EU official told AFP.
The first two, both on Monday, resulted in the EU being given "unsatisfactory" answers, European health commissioner Stella Kyriakides said afterwards.
While Soriot revealed some of the terms of the contract signed with the European Commission, the full contract remains confidential at AstraZeneca's demand.
The Commission was to brief journalists in further detail on its response and on the increasingly bitter feud that has erupted with the pharmaceutical firm.
The delay, coming on top of one announced two weeks ago by BioNTech/Pfizer, threatens to scupper the Commission's goal of having 70 percent of all adults in the EU vaccinated against Covid-19 by the end of August.
Already the rollout of jabs is trailing well behind Britain, the United States and Israel on a per capita basis.
Two vaccines are currently authorised for use across the 27-nation bloc: the BioNTech-Pfizer and Moderna jabs.